Tehran University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! On (X network) By
Neutralizing Antibody Production Against Rebif® and Recigen® in Relapsing-Remitting Multiple Sclerosis (Rrms) Patients and Its Association With Patient's Disability Publisher Pubmed



Shokrollahi Barough M1, 4 ; Ashtari F2 ; Sadat Akhavi M4 ; Asghari N3 ; Mosayebi G5 ; Mirmohammadkhani M3 ; Kokhaei N2 ; Bahraminia F6 ; Ajami A7 ; Kokhaei P8, 9
Authors
Show Affiliations
Authors Affiliations
  1. 1. Cancer Immunotherapy and Regenerative Medicine Department, Breast Cancer Research Center, Motamed Cancer Institute, ACECR, Tehran, Iran
  2. 2. Department of Neurology, School of Medicine and Isfahan Neuroscience Research Centre, Isfahan University of Medical Sciences, Isfahan, Iran
  3. 3. Faculty of Medicine, Semnan University of Medical Sciences, Semnan, Iran
  4. 4. Student's Research Committee, Semnan University of Medical Sciences, Semnan, Iran
  5. 5. Molecular and Medicine Research Center, Arak University of Medical Sciences, Arak, Iran
  6. 6. Department of Clinical Sciences, Faculty of Veterinary Medicine, Ferdowsi University of Mashhad, Mashhad, Iran
  7. 7. Department of Radiopharmacy, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran
  8. 8. Cancer Research Center, Semnan University of Medical Sciences, Semnan, Iran
  9. 9. Immune Gene therapy Lab, CCK, Karolinska University Hospital Solna, Stockholm, Sweden

Source: International Immunopharmacology Published:2018


Abstract

Introduction: Human recombinant interferon beta (IFN-β) is one of the first line treatments for Relapsing-Remitting Multiple Sclerosis (RRMS). However, the production of neutralizing antibodies (NAb) can impair its function. The aim of this study was to investigate the production of neutralizing antibodies against Rebif® and ReciGen® (two brands of IFN-β-1a) and to evaluate its correlation with Expanded Disability Status Scale (EDSS). Materials and methods: Serum samples of 71 RRMS patients (34 in ReciGen® 37 in Rebif® group) were collected. Neutralizing antibody was measured by Myxo-virus resistance protein A (MxA) assay using A549 cell line. The MxA concentration was measured by enzyme-linked immunosorbent assay (ELISA) kit. Results: The median period of treatment with IFN-β-1a was 18 months in ReciGen® and 24 months in Rebif® arms. The percentage of patients with positive titer of neutralizing antibody (NAb+) had no statistically significant difference between groups (P = 0.6). In both ReciGen® and Rebif® groups, the increase in EDSS score was significantly higher in NAb+ patients compared to NAb− patients (p ≤ 0.05). The duration of using ReciGen® or Rebif® for >24 months was influential in the NAb positivity (OR = 3.78). Conclusion: Receiving interferon beta-1a for >24 months is correlated with higher possibility of NAb production. The type of IFN-β used in the study had no significant impact on NAb positivity. In addition, both groups had comparable EDSS score changes, and NAb status of patients was correlated with their EDSS score. © 2018 Elsevier B.V.